Last reviewed · How we verify
NCT05239975
A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine
Phase 2 trial testing SCTV01C in COVID-19. Withdrawn.
1 July 2022
Quick facts
| Lead sponsor | Sinocelltech Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Start date | 25 April 2022 |
| Primary completion | 1 July 2022 |
| Estimated completion | 1 February 2023 |
Drugs / interventions tested
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →
Sponsor
Sinocelltech Ltd. — full company profile →
Who can join
12 and older, any sex, with COVID-19 or SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to evaluate the immunogenicity and safety of SCTV01C in participants aged ≥12 years and previously fully immunized with inactivated COVID-19 vaccine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05239975
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SCTV01C
Trials testing the same drug.
- NCT05323461 — A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Ye · Phase 3 · unknown
- NCT05239806 — A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years · Phase 2 · unknown
- NCT05308602 — A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in · Phase 2 · withdrawn
- NCT05238454 — A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previous · Phase 2 · unknown
- NCT05043285 — The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COV · Phase 1, PHASE2 · unknown
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Sinocelltech Ltd. trials
Trials by the same sponsor.
- NCT07244510 — Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa · Phase 2 · not yet recruiting
- NCT07077252 — Phase I/II Study of SCTB39G in Advanced Solid Tumours · Phase 1, PHASE2 · not yet recruiting
- NCT07050641 — Phase I/II Study of SCTB39-1 in Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06769984 — A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. · Phase 1, PHASE2 · not yet recruiting
- NCT06801509 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05239975 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinocelltech Ltd.
- Last refreshed: 9 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05239975.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing